OpGen is a precision medicine company engaged in molecular diagnostics and informatics. Along with its subsidiaries, Curetis GmbH and Ares Genetics GmbH, Co. is developing and commercializing molecular microbiology solutions helping to guide clinicians with actionable information about life threatening infections. Co.'s existing product portfolio includes Unyvero, Acuitas Antimicrobial Resistance (AMR) Gene Panel, and the ARES Technology Platform including ARES reference database on antimicrobial resistance, Next Generation Sequencing technology and Artificial Intelligence-powered bioinformatics solutions for AMR surveillance, outbreak analysis, and antibiotic response prediction. The OPGN average annual return since 2015 is shown above.
The Average Annual Return on the OPGN average annual return since 2015 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether OPGN average annual return since 2015 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the OPGN average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|